Results 221 to 230 of about 98,145 (299)

Association of Neutrophil‐to‐Lymphocyte and Platelet‐to‐Lymphocyte Ratios With Three‐Vessel Coronary Artery Disease: A Case‐Control Study

open access: yesHealth Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims Coronary artery disease (CAD) is a leading cause of mortality worldwide, with inflammation playing a crucial role in its pathogenesis. The neutrophil‐to‐lymphocyte ratio (NLR) and platelet‐to‐lymphocyte ratio (PLR) are emerging as potential inflammatory biomarkers for CAD severity. This study investigates the association of
Ladan Ayazkhoo   +5 more
wiley   +1 more source

Association Between Polymorphisms rs11003125 and rs7096206 of the MBL2 Gene and the Stages of Hepatitis B Progression in Burkina Faso: A Comparative Cross‐Sectional Study

open access: yesHealth Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Objectives Hepatitis B virus (HBV) infection remains a major global health burden, with disease progression influenced by host genetic and immune factors, including variants in the mannose‐binding lectin 2 (MBL2) gene. This study aimed to evaluate the association between MBL2 polymorphisms and clinical outcomes of HBV infection ...
Minane Nafissa Triande   +13 more
wiley   +1 more source

Cancer risks and trends between 1997 and 2018, and effects of restored immunity in people living with HIV: Results from the ANRS CO4 French hospital database on HIV

open access: yesInternational Journal of Cancer, Volume 158, Issue 9, Page 2298-2308, 1 May 2026.
What's new? This large nation‐wide cohort study provides a comprehensive 20‐year analysis of cancer trends among people living with HIV in France, highlighting persistent excess risks for virus‐related cancers despite effective antiretroviral therapy and immune restoration.
Sophie Grabar   +14 more
wiley   +1 more source

Hepatitis C test uptake among historic blood transfusion recipients following media coverage of the Penrose Inquiry and an awareness-raising campaign [PDF]

open access: yes, 2019
Anderson   +30 more
core   +1 more source

Carbohydrate‐Based Drug Discovery: Synthetic Strategies and Clinical Applications

open access: yesIsrael Journal of Chemistry, Volume 66, Issue 3, May 2026.
The picture depicts the molecules discussed in the review. On the left side, the general scaffold of sugars is shown. Next to it are four carbohydrate‐based molecules, including remdesivir, islatravir, empagliflozin, and Globo‐H. Remdesivir and islatravir contain a substituted ribose ring attached to a modified nucleobase.
Stephan Scheeff   +2 more
wiley   +1 more source

Cyclic Peptide Conformational Landscapes Through the Lens of Mass Spectrometry and Orthogonal Spectroscopy

open access: yesJournal of Mass Spectrometry, Volume 61, Issue 5, May 2026.
ABSTRACT Cyclic peptides occupy a structurally dynamic region of chemical space, where function often arises from ensembles rather than a single dominant fold. Closed backbones, frequent N‐methylation, heteroatoms, unnatural amino acids, and a strong propensity for metal coordination create dense conformational and coordination landscapes that ...
Emmanuel Nkyaagye   +2 more
wiley   +1 more source

Hepatitis C Virus and Type 2 Diabetes: Mechanisms, Clinical Impact, and Post‐DAA Management

open access: yesJournal of Medical Virology, Volume 98, Issue 5, May 2026.
ABSTRACT Hepatitis C virus (HCV) infection remains a major global health burden despite advances in direct‐acting antiviral (DAA) therapies. Beyond hepatic complications such as cirrhosis and hepatocellular carcinoma (HCC), HCV has been strongly linked to metabolic disorders, particularly type 2 diabetes mellitus (T2DM).
Shen‐Shong Chang   +3 more
wiley   +1 more source

Efficacy and Safety of 12‐Week Coblopasvir/Sofosbuvir Regimen for Hepatitis C in Northwest China: A Multi‐Center Prospective Study

open access: yesJournal of Medical Virology, Volume 98, Issue 5, May 2026.
ABSTRACT To assess the sustained virologic response (SVR12) and safety profile of 12‐week coblopasvir/sofosbuvir (COB/SOF) therapy in hepatitis C virus (HCV)‐infected patients across genotypes in Northwest China. This prospective cohort study (2023–2024) enrolled HCV patients from 12 clinical centers in Northwest China, adhering to the China Hepatitis ...
Lu Yan   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy